Medicare's CBD Pilot Program: Eligibility, Risks, and Future

0:00It's April 1st. Welcome to Durham News Today, powered by AI. I'm Corey with the story. Medicare just rolled out a pilot program reimbursing folks for hemp derived CVD products up to $500 a year for eligible beneficiaries in three specific care models. This is a big shift for the program serving about 65 million Americans since it never covered cannabis stuff before. But right before the April 1st launch, advocacy groups sue to shut it down, claiming and breaks federal rules. The substance access beneficiary engagement incentive lets participating health organizations provide these low THC CVD items at no cost to patients. As long as doctors approve and products pass strict tests for purity, no inhalables allowed and it excludes pregnant people or those with certain conditions. Medicare isn't paying directly. The organizations foot the bill while CMS tracks outcomes. Critics like smart approaches to marijuana say this skips proper rulemaking and treats unapproved

1:02CVD like drugs, unlike the one FDA-OKed version. For epilepsy, they worry about spotty quality and store-bought products for seniors. Meanwhile, CMS head Dr. Mehmed Oz calls it a smart research push to test real-world results on Medicare patients. About 14 million beneficiaries are in these accountable care organizations so the stakes are high if it expands. At a November 12th, 2026 deadline looms when new hemp laws slash THC limits way down, potentially wiping out most eligible products. Providers and patients should check eligibility in risks with doctors now since the lawsuit and law changes could end access fast. Stay tuned as courts and Congress sort this out for better options down the line.